Plasma Epstein-Barr virus (EBV) DNA as a biomarker for EBV-associated Hodgkin lymphoma

Dinand, Véronique; Anupam, Sachdeva; Datta, Sanghamitra; Bhalla, Sunita; Kalra, Manas; Wattal, Chand; Radhakrishnan, Nita

doi:10.1007/s13312-015-0696-9

Cited by 10 publications

(8 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Similarly, recent data suggests that EBV DNA expression in peripheral blood may be used as a clinical predictor of disease burden and monitoring response to therapy during disease course [30, 31]. …”

Section: Discussionmentioning

confidence: 99%

Latent membrane protein 1 (LMP1) expression in Hodgkin lymphoma and its correlation with clinical and histologic parameters

et al. 2017

View full text Add to dashboard Cite

BackgroundHodgkin lymphoma is one of the most prevalent lymphoproliferative disorders in Pakistan; however, no risk factors for this disease have yet to be established in our population. Epstein–Barr virus (EBV) is a well-known risk factor for Hodgkin lymphoma in endemic regions of the world; however, frequency of its association in our population has not been widely studied. Latent membrane protein 1 (LMP1) expression by immunohistochemistry (IHC) is a surrogate marker of EBV in Hodgkin lymphoma. Therefore, we aimed to evaluate the frequency of expression of LMP1 in cases of Hodgkin lymphoma at our institute and its correlation with other clinical and histologic parameters.MethodsThe study included 66 cases of Hodgkin lymphoma diagnosed at Liaquat National Hospital over a duration of 2 years from January 2014 to December 2015. The slides and blocks of all cases were retrieved, and representative blocks were selected for LMP1 by IHC. LMP1 expression of >10% of cells was considered as positive expression and correlated with histologic subtypes and clinical parameters like age, gender, and site of involvement.ResultsThe mean age of patients was 35.11 (+20.22). LMP1 expression was found in 68.1% (45/66) of cases of Hodgkin lymphoma. Mean age of the patients with LMP1 expression was 32.04 (+21.02). LMP1 expression was found in 40% cases of lymphocyte-rich, 66.7% of lymphocyte-depleted, 73.9% of mixed cellularity, 66.7% of nodular sclerosis, and 73.7% of classic Hodgkin lymphoma, NOS. No significant correlation of LMP1 expression with any clinical or histological parameter could be established in our studied patient population.ConclusionsA high frequency of expression of LMP1 is seen in cases of Hodgkin lymphoma at our setup comparable to endemic regions of the world; therefore, preventive and treatment protocols should be designed accordingly.

show abstract

Section: Discussionmentioning

confidence: 99%

Latent membrane protein 1 (LMP1) expression in Hodgkin lymphoma and its correlation with clinical and histologic parameters

et al. 2017

View full text Add to dashboard Cite

show abstract

“…Additionally, the performance of viral load testing using blood or liver biopsy at the earliest plays a pivotal role in establishing the underlying etiology. [ 14 ] To conclude, EBV infection has a varied spectrum of clinical presentation from mild self-limiting IM to complications like CAEBV, AIH, chronic hepatitis, and lymphoproliferative disorders. Hence, this varied clinical scenario should always be borne in mind of treating physicians especially among cases with IM symptoms persisting beyond 3 months.…”

Section: Discussionmentioning

confidence: 99%

Diagnostic dilemmas in Epstein-Barr virus hepatitis mimicking autoimmune hepatitis: A case report

Ramachandran

Agarwal

Bihari

et al. 2020

J Family Med Prim Care

View full text Add to dashboard Cite

We report a case of 55-year-old female with chief complaints of fever and deranged liver function tests, diagnosed as autoimmune hepatitis (AIH) and under immunosuppressive therapy for two years. Following the failure in clinical improvement, she was started on anti-tubercular therapy (ATT). While investigating the underlying etiology, virological markers for Hepatitis A to E were found to be negative with plasma Epstein-Barr virus (EBV) viral load of 5 log 10 copies/ml. Additional investigation of the liver biopsy showed Hodgkin's lymphoma (HL). The patient was initiated on chemotherapy but eventually succumbed to the illness. This case report underlines the dilemma in the initial diagnosis of AIH and the importance of considering hepatic involvement of EBV as one of the differential diagnosis among clinically suspected AIH cases not responding to immunosuppressive medications.

show abstract

“…Kanakry и соавт., что позволило авторам предложить использовать концентрацию вирусной ДНК в качестве маркера клинического статуса кЛХ, а также выявлять больных, резистентных к терапии [22]. К этим же выводам приходят и другие исследователи [20,23]. Их наблюдения свидетельствуют о том, что уровень ДНК ВЭБ, исходно обнаруживаемый в плазме больных с ВЭБ-ассоциированными формами кЛХ, становится неопределяемым после успешно проведенной терапии и существенно повышается при рецидивах болезни.…”

Section: клиническая онкогематологияunclassified

Epstein-Barr Virus in Patients with Classical Hodgkin’s Lymphoma

Gurtsevitch¹,

Демина²,

Senyuta³

et al. 2018

Клиническая онкогематология

View full text Add to dashboard Cite

Background. A close relationship between Epstein-Barr virus (EBV) and classical Hodgkin’s lymphoma (cHL) has been established in approximately 1/3 patients. EBV-positive lymphomas are characterized by increased level of EBV specific antibodies emerging long before tumor symptoms, аs well as a high plasma EBV DNA concentration. These viral markers normally correlate with clinical manifestations and the outcome of treatment performed. In patients with EBV-negative lymphomas, however, there has been no attempt to assess the clinical significance of either humoral response to EBV or EBV DNA concentration in plasma. Aim. To evaluate diagnostic and prognostic significance of EBV markers in patients with EBV-negative lymphomas. Methods. The clinical trial included 13 cHL-patients admitted at the Department of chemotherapy of hemoblastoses of NN Blokhin National Medical Cancer Research Center. The male to female ratio was 1: 1.3, the median age was 26.4 years. Leukocyte and lymphocyte counts were evaluated in all the patients before, during, and after treatment as well as throughout the follow-up period. The same indicators were analysed in the control group which contained 80 healthy persons (with the median age of 29.4 years, male to female ratio 1.5: 1). The study was based on serologic test for EBV antibodies and quantitative analysis of the viral DNA copy number in plasma. Results. The obtained data show a low immunie response to EBV and its diminishment after several polychemotherapy treatment cycles, correlating with decreased leukocyte and lymphocyte levels. As opposed to levels of virus-specific antibodies which do not reflect the efficacy of anticancer therapy, plasma EBV DNA concentration in 2 patients decreased to 0 after remission had been achieved. Conclusion. Although the number of observations is limited, one could suggest that viral load values in plasma of patients with EBV-negative lymphomas can prove to be a useful marker of anticancer therapeutic effect. Additional studies of these markers are required.

show abstract

Plasma Epstein-Barr virus (EBV) DNA as a biomarker for EBV-associated Hodgkin lymphoma

Abstract: Plasma EBV-DNA, detectable in EBV-associated Hodgkin lymphoma, becomes undetectable early after initiating therapy. It can be used as a biomarker of treatment response in EBV-associated Hodgkin lymphoma.

Cited by 10 publications

References 14 publications

Latent membrane protein 1 (LMP1) expression in Hodgkin lymphoma and its correlation with clinical and histologic parameters

Latent membrane protein 1 (LMP1) expression in Hodgkin lymphoma and its correlation with clinical and histologic parameters

Diagnostic dilemmas in Epstein-Barr virus hepatitis mimicking autoimmune hepatitis: A case report

Epstein-Barr Virus in Patients with Classical Hodgkin’s Lymphoma

Contact Info

Product

Resources

About